FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to liquid compositions G-CSF (granulocyte colonystimulating factor), and a method for preparing them. Particularly, the invention refers to a liquid composition containing G-CSF in the amount of 0.01 to 5.0 mg/ml as a biologically active substance, acetate - as a buffer, polysorbate 20 and/or polysorbat 80 as a surfactant and optionally pharmaceutically acceptable excipients with the composition having the pH value varying in the range 4.1 to 4.4.
EFFECT: composition possess storage-stability.
17 cl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION CONTAINING ACTIVE PRINCIPLE AND SULFOBETAINE | 2004 |
|
RU2380112C2 |
| IMPROVED METHOD OF PEGYLATING PROTEINS | 2009 |
|
RU2472806C1 |
| STABLE PHARMACEUTICAL COMPOSITION | 2017 |
|
RU2736830C2 |
| RECOMBINANT MONOCLONAL ANTIBODY TO TNF-ALPHA AQUEOUS PHARMACEUTICAL COMPOSITION | 2016 |
|
RU2665966C2 |
| AQUEOUS PHARMACEUTICAL COMPOSITION OF A RECOMBINANT MONOCLONAL ANTIBODY TO TNF-α | 2017 |
|
RU2764521C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING AGONIST GLP-1, INSULIN AND METHIONINE | 2010 |
|
RU2537239C2 |
| LIQUID FORMULATIONS FOR LONG-ACTING CONJUGATE OF G-CSF | 2011 |
|
RU2519031C1 |
| NOVEL STABILISER FOR PHARMACEUTICAL PROTEINS | 2011 |
|
RU2571496C2 |
| LIQUID COMPOSITION OF LONG-ACTING ALPHA INTERFERON CONJUGATE | 2011 |
|
RU2613905C2 |
| NOVEL PHARMACEUTICAL COMPOSITION | 2001 |
|
RU2281116C2 |
